Literature DB >> 31940273

Tumor Immunology and Tumor Evolution: Intertwined Histories.

Jérôme Galon1, Daniela Bruni2.   

Abstract

Cancer is a complex disease whose outcome depends largely on the cross-talk between the tumor and its microenvironment. Here, we review the evolution of the field of tumor immunology and the advances, in lockstep, of our understanding of cancer as a disease. We discuss the involvement of different immune cells at distinct stages of tumor progression and how immune contexture determinants shaping tumor development are being exploited therapeutically. Current clinical stratification schemes focus on the tumor histopathology and the molecular characteristics of the tumor cell. We argue for the importance of revising these stratification systems to include immune parameters so as to address the immediate need for improved prognostic and/or predictive information to guide clinical decisions.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  T cells; adaptive immunity; immune contexture; immunoscore; immunotherapy; tumor microenvironment; tumor-immunology

Year:  2020        PMID: 31940273     DOI: 10.1016/j.immuni.2019.12.018

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  141 in total

Review 1.  How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy.

Authors:  Jinyang Li; Ben Z Stanger
Journal:  Cancer Res       Date:  2020-06-18       Impact factor: 12.701

Review 2.  Antibodies specific for disease-associated antigens (DAA) expressed in non-malignant diseases reveal potential new tumor-associated antigens (TAA) for immunotherapy or immunoprevention.

Authors:  Camille Jacqueline; Olivera J Finn
Journal:  Semin Immunol       Date:  2020-04-06       Impact factor: 11.130

3.  Myeloid signature reveals immune contexture and predicts the prognosis of hepatocellular carcinoma.

Authors:  Chong Wu; Jie Lin; Yulan Weng; Dan-Ni Zeng; Jing Xu; Shufeng Luo; Li Xu; Mingyu Liu; Qiaomin Hua; Chao-Qun Liu; Jin-Qing Li; Jing Liao; Cheng Sun; Jian Zhou; Min-Shan Chen; Chao Liu; Zhenhong Guo; Shi-Mei Zhuang; Jin-Hua Huang; Limin Zheng
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

4.  Design, synthesis and biological evaluation of isoxazole-containing biphenyl derivatives as small-molecule inhibitors targeting the programmed cell death-1/ programmed cell death-ligand 1 immune checkpoint.

Authors:  Peiyu Zhu; Jian Zhang; Yifei Yang; Lixun Wang; Jinpei Zhou; Huibin Zhang
Journal:  Mol Divers       Date:  2021-03-30       Impact factor: 2.943

Review 5.  The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.

Authors:  Daniela Bruni; Helen K Angell; Jérôme Galon
Journal:  Nat Rev Cancer       Date:  2020-08-04       Impact factor: 60.716

6.  Detecting Tumor Antigen-Specific T Cells via Interaction-Dependent Fucosyl-Biotinylation.

Authors:  Zilei Liu; Jie P Li; Mingkuan Chen; Mengyao Wu; Yujie Shi; Wei Li; John R Teijaro; Peng Wu
Journal:  Cell       Date:  2020-10-22       Impact factor: 41.582

Review 7.  Host-microbiota maladaptation in colorectal cancer.

Authors:  Alina Janney; Fiona Powrie; Elizabeth H Mann
Journal:  Nature       Date:  2020-09-23       Impact factor: 49.962

8.  Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer.

Authors:  Bernhard Mlecnik; Carlo Bifulco; Gabriela Bindea; Florence Marliot; Alessandro Lugli; J Jack Lee; Inti Zlobec; Tilman T Rau; Martin D Berger; Iris D Nagtegaal; Elisa Vink-Börger; Arndt Hartmann; Carol Geppert; Julie Kolwelter; Susanne Merkel; Robert Grützmann; Marc Van den Eynde; Anne Jouret-Mourin; Alex Kartheuser; Daniel Léonard; Christophe Remue; Julia Y Wang; Prashant Bavi; Michael H A Roehrl; Pamela S Ohashi; Linh T Nguyen; SeongJun Han; Heather L MacGregor; Sara Hafezi-Bakhtiari; Bradly G Wouters; Giuseppe V Masucci; Emilia K Andersson; Eva Zavadova; Michal Vocka; Jan Spacek; Lubos Petruzelka; Bohuslav Konopasek; Pavel Dundr; Helena Skalova; Kristyna Nemejcova; Gerardo Botti; Fabiana Tatangelo; Paolo Delrio; Gennaro Ciliberto; Michele Maio; Luigi Laghi; Fabio Grizzi; Tessa Fredriksen; Bénédicte Buttard; Lucie Lafontaine; Daniela Bruni; Anastasia Lanzi; Carine El Sissy; Nacilla Haicheur; Amos Kirilovsky; Anne Berger; Christine Lagorce; Christopher Paustian; Carmen Ballesteros-Merino; Jeroen Dijkstra; Carlijn van de Water; Shannon van Lent-van Vliet; Nikki Knijn; Ana-Maria Muşină; Dragos-Viorel Scripcariu; Boryana Popivanova; Mingli Xu; Tomonobu Fujita; Shoichi Hazama; Nobuaki Suzuki; Hiroaki Nagano; Kiyotaka Okuno; Toshihiko Torigoe; Noriyuki Sato; Tomohisa Furuhata; Ichiro Takemasa; Kyogo Itoh; Prabhu S Patel; Hemangini H Vora; Birva Shah; Jayendrakumar B Patel; Kruti N Rajvik; Shashank J Pandya; Shilin N Shukla; Yili Wang; Guanjun Zhang; Yutaka Kawakami; Francesco M Marincola; Paolo A Ascierto; Bernard A Fox; Franck Pagès; Jérôme Galon
Journal:  J Clin Oncol       Date:  2020-09-08       Impact factor: 44.544

Review 9.  Chemokines and the immune response to cancer.

Authors:  Aleksandra J Ozga; Melvyn T Chow; Andrew D Luster
Journal:  Immunity       Date:  2021-04-10       Impact factor: 31.745

10.  Germline genetic contribution to the immune landscape of cancer.

Authors:  Rosalyn W Sayaman; Mohamad Saad; Vésteinn Thorsson; Donglei Hu; Wouter Hendrickx; Jessica Roelands; Eduard Porta-Pardo; Younes Mokrab; Farshad Farshidfar; Tomas Kirchhoff; Randy F Sweis; Oliver F Bathe; Carolina Heimann; Michael J Campbell; Cynthia Stretch; Scott Huntsman; Rebecca E Graff; Najeeb Syed; Laszlo Radvanyi; Simon Shelley; Denise Wolf; Francesco M Marincola; Michele Ceccarelli; Jérôme Galon; Elad Ziv; Davide Bedognetti
Journal:  Immunity       Date:  2021-02-09       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.